Genentech, A Member of the Roche Group, US Medical Affairs, 1 DNA Way, South San Francisco, CA, 94080, USA.
Ther Innov Regul Sci. 2020 Jan;54(1):75-84. doi: 10.1007/s43441-019-00031-3. Epub 2020 Jan 6.
Pharmaceutical manufacturer medical information (MI) departments play an important role in providing medical information to health care professionals (HCPs) and patients. A survey was conducted to gather insights on the utility of MI services and to understand the information needs/preferences to support therapy decisions.
Patients (n=40) and HCPs (n=192) who requested medical information in a 3-month time frame from 4 companies were surveyed (15 questions for patients; 28 questions for HCPs).
Patients contacted MI departments for information on concerns about side effects, efficacy information, access/insurance coverage, how to take the medicine, switching medicine, how the medicine works, comparison to another medicine, medical condition information, and participating in trials. Patients reported that the medical information received changed the perception toward the treatment in the following ways: learned something new about the treatment, provided more confidence to talk to an HCP, and were potentially more likely to start treatment. Health care professionals requested medical information related to dosing, safety, patient selection, and differentiating between therapeutic options. The HCPs used the medical information to take an action (eg, managing treatment for patients or deciding to prescribe a medicine), to support informing-type of activities (eg, help guide discussions with patients, plan to use information for future treatment decisions/ discussion, help with insurance coverage determination, or help to enroll patients into ongoing clinical trials), and to meet an education need (eg, self-education or sharing information with practice/colleagues).
These results describe patients' and HCPs' information needs/preferences that provide MI departments potential areas for enhancing services.
制药公司的医学信息（MI）部门在向医疗保健专业人员（HCP）和患者提供医学信息方面发挥着重要作用。进行了一项调查，以收集有关 MI 服务实用性的见解，并了解支持治疗决策的信息需求/偏好。
在 3 个月的时间内，从 4 家公司请求医学信息的患者（n=40）和 HCP（n=192）接受了调查（患者 15 个问题；HCP 28 个问题）。
患者联系 MI 部门获取有关副作用、疗效信息、获取/保险覆盖范围、如何服用药物、换药、药物作用机制、与另一种药物比较、医疗状况信息以及参与试验的信息。患者报告说，他们收到的医学信息以以下方式改变了对治疗的看法：对治疗有了新的认识，更有信心与 HCP 交谈，并且更有可能开始治疗。医疗保健专业人员请求与剂量、安全性、患者选择和区分治疗选择有关的医学信息。HCP 使用医学信息采取行动（例如，为患者管理治疗或决定开处方），以支持告知型活动（例如，帮助指导与患者的讨论、计划将信息用于未来的治疗决策/讨论、帮助确定保险覆盖范围、或帮助将患者纳入正在进行的临床试验），并满足教育需求（例如，自我教育或与实践/同事分享信息）。
这些结果描述了患者和 HCP 的信息需求/偏好，为 MI 部门提供了增强服务的潜在领域。
